- Home
- ZKIN vs MTVA Comparison
ZKIN vs MTVA Comparison
Compare ZKIN & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZKIN
- MTVA
- Stock Information
- Founded
- ZKIN 2015
- MTVA 2014
- Country
- ZKIN China
- MTVA United States
- Employees
- ZKIN N/A
- MTVA 8
- Industry
- ZKIN Metal Fabrications
- MTVA
- Sector
- ZKIN Industrials
- MTVA
- Exchange
- ZKIN Nasdaq
- MTVA NYSE
- Market Cap
- ZKIN 6.5M
- MTVA 15.1M
- IPO Year
- ZKIN 2017
- MTVA N/A
- Fundamental
- Price
- ZKIN $2.41
- MTVA $0.65
- Analyst Decision
- ZKIN
- MTVA Strong Buy
- Analyst Count
- ZKIN 0
- MTVA 2
- Target Price
- ZKIN N/A
- MTVA $7.50
- AVG Volume (30 Days)
- ZKIN 6.6M
- MTVA 632.7K
- Earning Date
- ZKIN 01-01-0001
- MTVA 05-14-2025
- Dividend Yield
- ZKIN N/A
- MTVA N/A
- EPS Growth
- ZKIN N/A
- MTVA N/A
- EPS
- ZKIN N/A
- MTVA N/A
- Revenue
- ZKIN $108,199,877.00
- MTVA N/A
- Revenue This Year
- ZKIN N/A
- MTVA N/A
- Revenue Next Year
- ZKIN N/A
- MTVA N/A
- P/E Ratio
- ZKIN N/A
- MTVA N/A
- Revenue Growth
- ZKIN N/A
- MTVA N/A
- 52 Week Low
- ZKIN $0.82
- MTVA $0.63
- 52 Week High
- ZKIN $6.30
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- ZKIN 52.13
- MTVA N/A
- Support Level
- ZKIN $2.46
- MTVA N/A
- Resistance Level
- ZKIN $2.55
- MTVA N/A
- Average True Range (ATR)
- ZKIN 0.49
- MTVA 0.00
- MACD
- ZKIN -0.11
- MTVA 0.00
- Stochastic Oscillator
- ZKIN 16.38
- MTVA 0.00
About ZKIN ZK International Group Co. Ltd
ZK International Group Co Ltd is engaged in the manufacture and marketing of metal pipes. The company is specialized in producing double-press thin-walled stainless steel tubes and fittings, carbon steel tubes and fittings, single-press tubes and fittings, and stainless-steel strips. The products are used in restaurants, hotels, hospitals, firefighting, food, beverage, ships, engines, industrial seawater desalination and systems of direct-drinking water, cold /hot water supply, city water supply, and gas of large/middle scale construction projects.
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.